Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01138553 · ClinicalTrials.gov registry record · Early Phase 1
Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
A Early Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT01138553 is a Early Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 4 participants.
The verdict
NCT01138553, a Early Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone. This will be done by treating women briefly prior to planned surgery and examining the decrease in growth rate (measured by Ki-67 immunohistochemistry) in tumor samples taken before and after exposure to mifepristone.
Interventions
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01138553
The ClinicalTrials.gov registry entry for NCT01138553 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mifepristone is the first listed.
NCT01138553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01138553 about?
NCT01138553 is a clinical study titled "Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer". The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone. This will be done by treating women briefly prior to planned surgery and examining the de...
What is the current status of trial NCT01138553?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2010-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01138553?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT01138553?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.